{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T00:46:01Z","timestamp":1794962761306,"version":"4.9.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R01-CA265009"],"award-info":[{"award-number":["R01-CA265009"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007909","name":"Fibrolamellar Cancer Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007909","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41591-025-03995-y","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T10:02:22Z","timestamp":1763978542000},"page":"4246-4255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial"],"prefix":"10.1038","volume":"31","author":[{"given":"Marina","family":"Baretti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4286-3678","authenticated-orcid":false,"given":"Allison M.","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian H.","family":"Ladle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeal","family":"Kamdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4072-9002","authenticated-orcid":false,"given":"Kayla J.","family":"Bendinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2644-5086","authenticated-orcid":false,"given":"Won Jin","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0406-2498","authenticated-orcid":false,"given":"Samir","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8559-1660","authenticated-orcid":false,"given":"Balaji","family":"Sundararaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6489-6940","authenticated-orcid":false,"given":"Hao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng-Chung","family":"Kung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeric","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0072-5752","authenticated-orcid":false,"given":"Hanfei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7658-5899","authenticated-orcid":false,"given":"Sarah M.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6044-2631","authenticated-orcid":false,"given":"Alexei","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan A.","family":"Schattgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy Chase","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Furth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7743-9183","authenticated-orcid":false,"given":"Chris","family":"Thoburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0094-0049","authenticated-orcid":false,"given":"Neeha","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda L.","family":"Huff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Nauroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3841-6549","authenticated-orcid":false,"given":"Elizabeth","family":"Jaffee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail V.","family":"Pogorelyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7955-0256","authenticated-orcid":false,"given":"Paul G.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4401-0748","authenticated-orcid":false,"given":"Mark","family":"Yarchoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"3995_CR1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41575-022-00580-3","volume":"19","author":"TA Dinh","year":"2022","unstructured":"Dinh, T. A. et al. A framework for fibrolamellar carcinoma research and clinical trials. Nat. Rev. Gastroenterol. Hepatol. 19, 328\u2013342 (2022).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"3995_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2021.100770","volume":"45","author":"AF O\u2019Neill","year":"2021","unstructured":"O\u2019Neill, A. F. et al. Fibrolamellar carcinoma: an entity all its own. Curr. Probl. Cancer 45, 100770 (2021).","journal-title":"Curr. Probl. Cancer"},{"key":"3995_CR3","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/cncr.21703","volume":"106","author":"F Stipa","year":"2006","unstructured":"Stipa, F. et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer 106, 1331\u20131338 (2006).","journal-title":"Cancer"},{"key":"3995_CR4","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.1249484","volume":"343","author":"JN Honeyman","year":"2014","unstructured":"Honeyman, J. N. et al. Detection of a recurrent DNAJB1\u2013PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 343, 1010\u20131014 (2014).","journal-title":"Science"},{"key":"3995_CR5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nrclinonc.2017.127","volume":"14","author":"AM Schram","year":"2017","unstructured":"Schram, A. M., Chang, M. T., Jonsson, P. & Drilon, A. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. Nat. Rev. Clin. Oncol. 14, 735\u2013748 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3995_CR6","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41591-019-0434-2","volume":"25","author":"W Yang","year":"2019","unstructured":"Yang, W. et al. Immunogenic neoantigens derived from gene fusions stimulate T cell responses. Nat. Med. 25, 767\u2013775 (2019).","journal-title":"Nat. Med."},{"key":"3995_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33746-3","volume":"13","author":"J Bauer","year":"2022","unstructured":"Bauer, J. et al. The oncogenic fusion protein DNAJB1\u2013PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. Nat. Commun. 13, 6401 (2022).","journal-title":"Nat. Commun."},{"key":"3995_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101469","volume":"5","author":"AM Kirk","year":"2024","unstructured":"Kirk, A. M. et al. DNAJB1\u2013PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma. Cell Rep. Med. 5, 101469 (2024).","journal-title":"Cell Rep. Med."},{"key":"3995_CR9","doi-asserted-by":"publisher","unstructured":"Pogorelyy, M. V. et al. TIRTL-seq: deep, quantitative and affordable paired TCR repertoire sequencing. Nat. Methods https:\/\/doi.org\/10.1038\/s41592-025-02907-9 (2025).","DOI":"10.1038\/s41592-025-02907-9"},{"key":"3995_CR10","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1146\/annurev-immunol-042718-041757","volume":"37","author":"P Bradley","year":"2019","unstructured":"Bradley, P. & Thomas, P. G. Using T cell receptor repertoires to understand the principles of adaptive immune recognition. Annu Rev. Immunol. 37, 547\u2013570 (2019).","journal-title":"Annu Rev. Immunol."},{"key":"3995_CR11","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nature22383","volume":"547","author":"P Dash","year":"2017","unstructured":"Dash, P. et al. Quantifiable predictive features define epitope-specific T cell receptor repertoires. Nature 547, 89\u201393 (2017).","journal-title":"Nature"},{"key":"3995_CR12","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.immuni.2024.02.007","volume":"57","author":"A Franken","year":"2024","unstructured":"Franken, A. et al. CD4+ T cell activation distinguishes response to anti-PD-L1+ anti-CTLA4 therapy from anti-PD-L1 monotherapy. Immunity 57, 541\u2013558.e7 (2024).","journal-title":"Immunity"},{"key":"3995_CR13","doi-asserted-by":"publisher","unstructured":"Nakazawa, M. et al. Anti-CTLA4 therapy leads to early expansion of a peripheral Th17 population and induction of Th1 cytokines. Cancer Immunol. Res. https:\/\/doi.org\/10.1158\/2326-6066.CIR-24-1055 (2025).","DOI":"10.1158\/2326-6066.CIR-24-1055"},{"key":"3995_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s43018-022-00509-4","volume":"4","author":"V Thatikonda","year":"2023","unstructured":"Thatikonda, V. et al. Comprehensive analysis of mutational signatures reveals distinct patterns and molecular processes across 27 pediatric cancers. Nat. Cancer 4, 276\u2013289 (2023).","journal-title":"Nat. Cancer"},{"key":"3995_CR15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217\u2013221 (2017).","journal-title":"Nature"},{"key":"3995_CR16","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1634\/theoncologist.2020-0367","volume":"25","author":"I El Dika","year":"2020","unstructured":"El Dika, I. et al. A multicenter randomized three-arm phase II study of (1) everolimus, (2) estrogen deprivation therapy (EDT) with leuprolide + letrozole, and (3) everolimus + EDT in patients with unresectable fibrolamellar carcinoma. Oncologist 25, 925\u2013e1603 (2020).","journal-title":"Oncologist"},{"key":"3995_CR17","doi-asserted-by":"publisher","unstructured":"O\u2019Neill, A. F. et al. Clinical and immunophenotype correlating with response to immunotherapy in paediatric patients with primary liver carcinoma. A case series. eBioMedicine. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105147 (2024).","DOI":"10.1016\/j.ebiom.2024.105147"},{"key":"3995_CR18","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1200\/JCO.2021.39.3_suppl.310","volume":"39","author":"GK Abou-Alfa","year":"2021","unstructured":"Abou-Alfa, G. K. et al. Evaluation of neratinib (N), pembrolizumab (P), everolimus (E), and nivolumab (V) in patients (pts) with fibrolamellar carcinoma (FLC). JCO 39, 310\u2013310 (2021).","journal-title":"JCO"},{"key":"3995_CR19","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.3390\/cancers14215347","volume":"14","author":"KY Chen","year":"2022","unstructured":"Chen, K. Y. et al. Clinical outcomes in fibrolamellar hepatocellular carcinoma treated with immune checkpoint inhibitors. Cancers 14, 5347 (2022).","journal-title":"Cancers"},{"key":"3995_CR20","doi-asserted-by":"publisher","unstructured":"Martini, D. J. & Wu, C. J. The future of personalized cancer vaccines. Cancer Discov. https:\/\/doi.org\/10.1158\/2159-8290.CD-25-0300 (2025).","DOI":"10.1158\/2159-8290.CD-25-0300"},{"key":"3995_CR21","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","volume":"565","author":"N Hilf","year":"2019","unstructured":"Hilf, N. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565, 240\u2013245 (2019).","journal-title":"Nature"},{"key":"3995_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234\u2013239 (2019).","journal-title":"Nature"},{"key":"3995_CR23","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/s41586-023-05787-1","volume":"615","author":"C Puig-Saus","year":"2023","unstructured":"Puig-Saus, C. et al. Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy. Nature 615, 697\u2013704 (2023).","journal-title":"Nature"},{"key":"3995_CR24","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41586-019-1671-8","volume":"574","author":"E Alspach","year":"2019","unstructured":"Alspach, E. et al. MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature 574, 696\u2013701 (2019).","journal-title":"Nature"},{"key":"3995_CR25","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.174027","volume":"8","author":"AL Huff","year":"2023","unstructured":"Huff, A. L. et al. CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacy. JCI Insight 8, e174027 (2023).","journal-title":"JCI Insight"},{"key":"3995_CR26","doi-asserted-by":"publisher","unstructured":"Braun, D. A. et al. A neoantigen vaccine generates antitumour immunity in renal cell carcinoma. Nature https:\/\/doi.org\/10.1038\/s41586-024-08507-5 (2025).","DOI":"10.1038\/s41586-024-08507-5"},{"key":"3995_CR27","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"3995_CR28","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","volume":"30","author":"M Yarchoan","year":"2024","unstructured":"Yarchoan, M. et al. Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial. Nat. Med. 30, 1044\u20131053 (2024).","journal-title":"Nat. Med."},{"key":"3995_CR29","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet 403, 632\u2013644 (2024).","journal-title":"Lancet"},{"key":"3995_CR30","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41586-022-04696-z","volume":"606","author":"D Hoyos","year":"2022","unstructured":"Hoyos, D. et al. Fundamental immune\u2013oncogenicity trade-offs define driver mutation fitness. Nature 606, 172\u2013179 (2022).","journal-title":"Nature"},{"key":"3995_CR31","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s41591-022-01786-3","volume":"28","author":"SS Chandran","year":"2022","unstructured":"Chandran, S. S. et al. Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nat. Med. 28, 946\u2013957 (2022).","journal-title":"Nat. Med."},{"key":"3995_CR32","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","volume":"375","author":"E Tran","year":"2016","unstructured":"Tran, E. et al. T-cell transfer therapy targeting mutant KRAS in cancer. N. Engl. J. Med. 375, 2255\u20132262 (2016).","journal-title":"N. Engl. J. Med."},{"key":"3995_CR33","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41591-023-02760-3","volume":"30","author":"S Pant","year":"2024","unstructured":"Pant, S. et al. Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat. Med. 30, 531\u2013542 (2024).","journal-title":"Nat. Med."},{"key":"3995_CR34","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","volume":"386","author":"R Leidner","year":"2022","unstructured":"Leidner, R. et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N. Engl. J. Med. 386, 2112\u20132119 (2022).","journal-title":"N. Engl. J. Med."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03995-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03995-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03995-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:00:20Z","timestamp":1765814420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-025-03995-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3995"],"URL":"https:\/\/doi.org\/10.1038\/s41591-025-03995-y","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Bristol Myers Squibb provided nivolumab and ipilimumab and support for the clinical trial. M.B. reports advisory board from AstraZeneca. A.M.K holds a patent for a previously described fusion-specific TCR in FLC (US patent number 20220251167). W.J.H. reports patent royalties from Rodeo\/Amgen, received research funding from Sanofi, NeoTX, Riboscience (to Johns Hopkins), and speaking\/travel honoraria from Exelixis and Standard BioTools. S.M.S received travel honoraria from Standard Biotools. J.C.C. reports patents related to TCR amplification, cloning and\/or applications thereof and holds a patent for a previously described fusion-specific TCR in FLC (US patent numbers 20220251167, 20220326216, 20220136051). R.A.A. reports consulting arrangment with Bristol Myers Squib, AstraZeneca, Merck SD and Jazz Pharmaceuticals N.Z. reports research support from Bristol Myers Squibb, is a consultant for Genentech and receives other support from Adventris Pharmaceuticals. A.L.H. is a paid consultant of Adventris Pharmaceuticals, Inc. E.J. reports other support from Abmeta and Adventris, personal fees from Dragonfly, Neuvogen, STIMIT Tx, Mestag, Candel therapeutics, HDTbio, and grants from Lustgarten, Genentech, BMS, NeoTx, and Break Through Cancer. E.J. is a founder of and holds equity in Adventris Pharmaceuticals. She also serves as a consultant to the entity. M.V.P. has patents related to TCR amplification, cloning and\/or applications thereof (US patent numbers 20250116673, 20250066852). P.G.T. is on the Scientific Advisory Board of Immunoscape and Shennon Bio; has received research support and personal fees from Elevate Bio; and consulted for CellCarta, RAVentures, 10X Genomics, Illumina, Pfizer, Cytoagents, Sanofi, Merck and JNJ. M.Y. receives grant\/research support (to Johns Hopkins) from Bristol Myers Squibb, Exelixis, Incyte and Genentech; receives honoraria from Exelixis, AstraZeneca, Lantheus, Genentech and Incyte; is the coinventor of patents related to therapeutic cancer vaccines (managed by Johns Hopkins, US patent number 20230173049); and is a cofounder with equity of Adventris Pharmaceuticals. M.B., A.M.K, J.C.C., M.V.P., P.G.T. and M.Y. are coinventors on a pending patent application for the fusion-specific TCRs described herein. B.H.L., Z.K., K.J.B., S.A., N.A.C, B.S., H.W., H.-C.K., J.H., H. Q., A.H., M.N., S.A.S., M.F., R.A.A., C.T., A.G. and J.N. have no reported disclosures related to the current work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}